NICE recommends two treatments for DMO
The National Institute for Health and Care Excellence has recommended aflibercept and a dexamethasone implant for diabetic macular oedema
The National Institute for Health and Care Excellence (NICE) has recommended two treatment options for diabetic macular oedema (DMO), publishing two separate pieces of guidance today (22 July).
The final guidance from the regulatory agency has approved the use of the anti-VEGF treatment aflibercept, marketed as Eylea by Bayer Pharma, for patients with a central retinal thickness of 400µm or more at the start of treatment. A restriction of the recommendation is the provision of the drug discounted under an agreed patient access scheme.
The second recommendation is for a dexamethsone intravitreal implant. The final guidance states that the treatment is only suitable for DMO patients with an intraocular lens who are non responsive to non-corticosteroid treatment, or such treatment is unsuitable.
Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE, said: “Whilst these recommendations are for people with diabetic macular oedema needing different treatments at different stages of the disease, these decisions will be welcome news to both patients and healthcare professionals alike.”